Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leading biotechnology company focused on the discovery and development of RNA interference-based therapeutics. Founded in 2002 by pioneering scientists in the RNA field, the company has translated fundamental discoveries in gene silencing into a robust commercial platform. Its work has established a new class of medicines, with multiple approved products for rare genetic diseases. The company's headquarters are located in the Kendall Square area of Cambridge, Massachusetts.

History

The company was founded in 2002 based on groundbreaking work in RNA interference by scientific founders including Nobel Prize laureate Phillip Sharp and Thomas Tuschl. Early research and development were supported by venture capital firms such as Polaris Partners and ARCH Venture Partners. A significant early milestone was a major collaboration and license agreement with Roche in 2007, which provided validation and resources. The company faced a pivotal moment in 2010 when Roche and later Novartis paused their RNAi programs, leading to a strategic refocusing on rare diseases with liver-targeted delivery. This shift culminated in the landmark 2018 approval of Onpattro by the U.S. Food and Drug Administration and the European Medicines Agency, marking the first-ever approved RNAi therapeutic.

Technology and platform

The core technology is built upon the natural biological process of RNA interference, which mediates gene silencing. The company's platform utilizes small interfering RNA molecules designed to bind specifically to messenger RNA sequences. A critical innovation is the GalNAc conjugate delivery platform, which enables targeted delivery to hepatocytes in the liver. This platform technology has been foundational for most of its development candidates. The company continues to advance next-generation delivery technologies, including efforts targeting tissues beyond the liver, such as the central nervous system and eye. These advancements are supported by ongoing research at institutions like the Massachusetts Institute of Technology and Alnylam's own R&D.

Products and pipeline

The company's first commercial product, Onpattro, is approved for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. This was followed by Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio, developed in partnership with Novartis, for hypercholesterolemia. Its most recent approval, Amvuttra, is for the treatment of polyneuropathy in hereditary transthyretin-mediated amyloidosis. The clinical pipeline includes investigational RNAi therapeutics for a range of diseases, including alpha-1 antitrypsin deficiency, hemophilia, and complement-mediated diseases. Several candidates are in development through alliances with companies like Regeneron Pharmaceuticals and Vir Biotechnology.

Collaborations and partnerships

Strategic alliances have been central to its development. Major pharmaceutical partners have included Roche, Novartis, Sanofi, and Takeda Pharmaceutical Company. A significant multi-target collaboration with Regeneron Pharmaceuticals was established in 2019 to discover and develop RNAi therapeutics for diseases of the eye, central nervous system, and liver. The company also has a partnership with Vir Biotechnology focused on infectious diseases. These collaborations often involve shared R&D efforts, milestone payments, and royalty-sharing arrangements. The company has also engaged in numerous licensing agreements with academic institutions like Massachusetts Institute of Technology and the University of Massachusetts.

Corporate affairs

The company is headquartered in Cambridge, Massachusetts, within the prominent Kendall Square biotech cluster. Its common stock is publicly traded on the Nasdaq stock exchange under the ticker symbol ALNY. Key leadership has included founding CEO John Maraganore, who led the company for nearly two decades, and his successor, Yvonne Greenstreet. The company has grown significantly since its initial public offering and maintains a global commercial and medical affairs presence. It has been recognized with awards such as the Prix Galien USA award for Onpattro. The company's operations and research activities are subject to oversight by regulatory bodies including the U.S. Food and Drug Administration and the European Medicines Agency.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Pharmaceutical companies established in 2002